Dimensional Fund Advisors LP Purchases 1,106,592 Shares of Iovance Biotherapeutics, Inc. $IOVA

Key Points

• Dimensional Fund Advisors increased its Iovance Biotherapeutics stake by 71.9%, purchasing 1.11 million additional shares to hold 2.65 million shares valued at approximately $9.28 million. Institutional investors collectively own 77.03% of the company.
• Analyst sentiment is mixed but leans cautiously positive: five analysts rate IOVA a Buy, three a Hold and two a Sell, with a consensus price target of $8.00. Citizens JMP and Barclays recently raised their targets, while Chardan Capital reduced its target to $14.
• Iovance reported quarterly revenue of $198.63 million, up 65.7% year over year and above estimates, while its loss of $0.11 per share beat expectations. Despite improving results and strong product demand, the company remains unprofitable, with a negative net margin of 89.11%.

Dimensional Fund Advisors LP lifted its holdings in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Free Report) by 71.9% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,645,702 shares of the biotechnology company's stock after purchasing an additional 1,106,592 shares during the quarter. Dimensional Fund Advisors LP owned 0.59% of Iovance Biotherapeutics worth $9,282,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in the business. KBC Group NV acquired a new stake in shares of Iovance Biotherapeutics in the 1st quarter valued at approximately $34,000. Annis Gardner Whiting Capital Advisors LLC acquired a new position in Iovance Biotherapeutics during the first quarter worth $352,000. Ceera Investments LLC bought a new stake in Iovance Biotherapeutics during the first quarter worth $44,000. Sanctuary Advisors LLC acquired a new stake in Iovance Biotherapeutics in the first quarter valued at $38,000. Finally, Chicago Partners Investment Group LLC grew its position in shares of Iovance Biotherapeutics by 29.7% in the 1st quarter. Chicago Partners Investment Group LLC now owns 52,653 shares of the biotechnology company's stock valued at $186,000 after acquiring an additional 12,064 shares during the period. Institutional investors and hedge funds own 77.03% of the company's stock.

Analyst Upgrades and Downgrades

A number of research firms recently commented on IOVA. Citizens Jmp lifted their price target on Iovance Biotherapeutics from $5.00 to $8.00 and gave the stock a "market outperform" rating in a report on Friday. Chardan Capital cut their price objective on Iovance Biotherapeutics from $16.00 to $14.00 and set a "buy" rating for the company in a research report on Thursday, May 7th. Barclays boosted their target price on Iovance Biotherapeutics from $11.00 to $13.00 and gave the stock an "overweight" rating in a report on Friday. Weiss Ratings restated a "sell (d-)" rating on shares of Iovance Biotherapeutics in a research note on Thursday, July 2nd. Finally, Robert W. Baird set a $6.00 price target on Iovance Biotherapeutics in a report on Friday. Five investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have issued a Sell rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus target price of $8.00.

Iovance Biotherapeutics Price Performance

Shares of IOVA stock opened at $6.34 on Monday. The business has a fifty day simple moving average of $4.40 and a 200 day simple moving average of $3.81. The company has a market cap of $2.87 billion, a P/E ratio of -8.68 and a beta of 0.71. Iovance Biotherapeutics, Inc. has a twelve month low of $1.76 and a twelve month high of $6.92.

Iovance Biotherapeutics (NASDAQ:IOVA - Get Free Report) last posted its earnings results on Thursday, August 6th. The biotechnology company reported ($0.11) earnings per share for the quarter, topping analysts' consensus estimates of ($0.13) by $0.02. Iovance Biotherapeutics had a negative net margin of 89.11% and a negative return on equity of 40.92%. The firm had revenue of $198.63 million for the quarter, compared to analysts' expectations of $87.83 million. During the same quarter in the previous year, the firm posted ($0.33) earnings per share. The company's revenue was up 65.7% on a year-over-year basis. As a group, equities research analysts anticipate that Iovance Biotherapeutics, Inc. will post -0.56 earnings per share for the current fiscal year.

Iovance Biotherapeutics News Roundup

Here are the key news stories impacting Iovance Biotherapeutics this week:

• Positive Sentiment: Record revenue and strong Amtagvi demand: Second-quarter revenue reached approximately $99.3 million, up 66% year over year and well above analyst expectations. U.S. Amtagvi revenue was about $91 million, rising 40% from the fourth quarter, helping drive the earnings beat. Iovance Q2 2026 results
• Positive Sentiment: Loss narrowed and margins improved: Iovance reported a loss of $0.11 per share, better than the $0.13–$0.17 consensus range and an improvement from $0.33 per share a year earlier. Gross margin increased to 56% as manufacturing and cost efficiencies improved. Zacks Q2 earnings report
• Positive Sentiment: Analyst support strengthened: Citizens JMP raised its IOVA price target from $5 to $8 and assigned a “market outperform” rating, reinforcing bullish sentiment following the results. Benzinga analyst update
• Positive Sentiment: Pipeline catalysts expanded: The FDA granted Fast Track Designation to lifileucel for soft tissue sarcomas. Investors are also focused on upcoming data from melanoma and non-small-cell lung cancer programs, with additional trial updates expected later this year. Iovance pipeline update
• Neutral Sentiment: Management is reviewing its 2026 revenue outlook of $350 million to $370 million because of stronger demand, but plans to provide an updated forecast in the third quarter. The company ended June with approximately $304 million in cash, expected to fund operations into the second half of 2028.
• Negative Sentiment: Iovance remains unprofitable, posting a quarterly net loss of approximately $47.3 million, while research and development expenses totaled $58.9 million. Continued losses and execution risks around commercialization and clinical trials remain important risks for investors.

About Iovance Biotherapeutics

Iovance Biotherapeutics, Inc is a clinical‐stage biotechnology company specializing in the development and commercialization of tumor‐infiltrating lymphocyte (TIL) immunotherapies for the treatment of solid tumors. The company's lead product candidate, lifileucel (formerly LN‐144), is an autologous TIL therapy in late‐stage clinical development for patients with advanced melanoma. Iovance's pipeline also includes next‐generation TIL programs such as LN‐145 for cervical and other human papillomavirus (HPV)‐related cancers, as well as exploratory studies in head and neck, non‐small cell lung, gastric and other solid tumor indications.

Iovance's TIL platform harnesses a patient's own immune system by isolating, expanding and reinfusing tumor‐reactive lymphocytes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source